Truist Financial Cuts Astrana Health (NASDAQ:ASTH) Price Target to $46.00

Astrana Health (NASDAQ:ASTH) had its target price reduced by Truist Financial from $50.00 to $46.00 in a report issued on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts have also issued reports on the stock. Robert W. Baird decreased their price target on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. Bank of America decreased their price objective on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Stifel Nicolaus decreased their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Finally, Macquarie raised shares of Astrana Health to a “hold” rating in a research note on Monday, December 16th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $56.17.

Astrana Health Trading Down 2.2 %

Astrana Health stock opened at $30.82 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. Astrana Health has a 1 year low of $23.12 and a 1 year high of $63.20. The firm’s 50 day moving average price is $33.95 and its two-hundred day moving average price is $42.67.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.37). The business had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. On average, research analysts predict that Astrana Health will post 1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

A number of institutional investors have recently modified their holdings of ASTH. Victory Capital Management Inc. acquired a new stake in shares of Astrana Health during the 3rd quarter valued at $2,596,000. KBC Group NV acquired a new stake in shares of Astrana Health during the 3rd quarter valued at $70,000. Natixis Advisors LLC acquired a new stake in shares of Astrana Health during the 3rd quarter valued at $1,621,000. Mutual of America Capital Management LLC acquired a new stake in shares of Astrana Health during the 3rd quarter valued at $362,000. Finally, Thrivent Financial for Lutherans acquired a new stake in shares of Astrana Health during the 3rd quarter valued at $1,890,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.